Novel endogenous angiogenesis inhibitors and their therapeutic potential

Acta Pharmacologica Sinica

Volumn 36, Issue 10, 2015, Pages 1177-1190

  Rao, Nithya ^a   Lee, Yu Fei ^a   Ge, Ruowen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

anti angiogenesis; ARHGAP18; cancer; CHIP; endogenous angiogenesis inhibitors; FKBPL; GPR56; ISM1; JWA; MMRN2; SOCS3; TAp73; ZNF24

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOXY VTERMINUS OF HSC70 INTERACTING PROTEIN; FK506 BINDING PROTEIN LIKE; G PROTEIN COUPLED RECEPTOR 56; ISTHMIN 1; JWA PROTEIN; MULTIMERIN 2; RHO GTPASE ACTIVATING PROTEIN 18; SUPPRESSOR OF CYTOKINE SIGNALING 3; TUMOR PROTEIN 73 ALPHA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN 24; PROTEIN;

ACTIN FILAMENT; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER INHIBITION; CELL ADHESION; CELL DEATH; CELL MIGRATION; CELL SHAPE; CELL SPREADING; DISTANT METASTASIS FREE SURVIVAL; ENDOCYTOSIS; ENDOPLASMIC RETICULUM STRESS; HUMAN; NONHUMAN; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SENESCENCE; TETRATRICOPEPTIDE REPEAT; TUMOR GROWTH; UBIQUITINATION; VASCULARIZATION; ANIMAL; DRUG DEVELOPMENT; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DISCOVERY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEINS;

EID: 84943232663     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2015.73     Document Type: Review

References (140)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat med 1995; 1: 27-31.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
6. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002; 6: 1-12.
7. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, et al. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 1999; 96: 14888-93.
8. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding YY, Abe M, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 2004; 114: 898-907.
9. Hiraki Y, Inoue H, Iyama K, Kamizono A, Ochiai M, Shukunami C, et al. Identification of chondromodulin I as a novel endothelial cell growth inhibitor-Purification and its localization in the avascular zone of epiphysical cartilage. J Biol Chem 1997; 272: 32419-26.
10. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-8.
11. Bikfalvi A, Gimenez-Gallego G. The control of angiogenesis and tumor invasion by platelet factor-4 and platelet factor-4-derived molecules. Semin Thromb Hemost 2004; 30: 137-44.
12. OReilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
13. Oreilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin-a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung-carcinoma. Cell 1994; 79: 315-28.
14. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000; 275: 21340-8.
15. Saran Kumar NR, Shruthi Venugopal, Ruowen Ge. Endogenous Angiogenesis Inhibitors: Is The List Ever Ending? In: Berhardt LV editors. Advances in Medicine and Biology ed: Nova Science Publishers 2012: 1-48.
16. Pera EM, Kim JI, Martinez SL, Brechner M, Li SY, Wessely O, et al. Isthmin is a novel secreted protein expressed as part of the Fgf-8 synexpression group in the Xenopus midbrain-hindbrain organizer. Mech Develop 2002; 116: 169-72.
17. Xiang W, Ke ZY, Zhang Y, Cheng GHY, Irwan ID, Sulochana KN, et al. Isthmin is a novel secreted angiogenesis inhibitor that inhibits tumour growth in mice. J Cell Mol Med 2011; 15: 359-74.
18. Chen M, Zhang Y, Yu VC, Chong YS, Yoshioka T, Ge R. Isthmin targets cell-surface GRP78 and triggers apoptosis via induction of mitochondrial dysfunction. Cell Death Differ 2014; 21: 797-810.
19. Zhang Y, Chen M, Venugopal S, Zhou Y, Xiang W, Li YH, et al. Isthmin exerts pro-survival and death-promoting effect on endothelial cells through alphavbeta5 integrin depending on its physical state. Cell Death Dis 2011; 2: e153.
20. Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 2011; 434: 181-8.
21. Klingenberg M. The ADP and ATP transport in mitochondria and its carrier. Biochim Biophys Acta 2008; 1778: 1978-2021.
22. Lee AS. GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res 2007; 67: 3496-9.
23. Schwarze S, Rangnekar VM. Targeting plasma membrane GRP78 for cancer growth inhibition. Cancer Biol Ther 2010; 9: 153-5.
24. Sato M, Yao VJ, Arap W, Pasqualini R. GRP78 signaling hub a receptor for targeted tumor therapy. Adv Genet 2010; 69: 97-114.
25. Yuan BQ, Xian RH, Ma JF, Chen YJ, Lin CG, Song YM. Isthmin inhibits glioma growth through antiangiogenesis in vivo. J Neuro Oncol 2012; 109: 245-52.
26. Robson T, Joiner MC, Wilson GD, McCullough W, Price ME, Logan I, et al. A novel human stress response-related gene with a potential role in induced radioresistance. Radiat Res 1999; 152: 451-61.
27. Robson T, Price ME, Moore ML, Joiner MC, McKelvey-Martin VJ, McKeown SR, et al. Increased repair and cell survival in cells treated with DIR1 antisense oligonucleotides: implications for induced radioresistance. Int J Radiat Biol 2000; 76: 617-23.
28. Kay JE. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem J 1996; 314: 361-85.
29. McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne C, et al. A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling. Endocrinology 2008; 149: 5724-34.
30. Sunnotel O, Hiripi L, Lagan K, McDaid JR, De Leon JM, Miyagawa Y, et al. Alterations in the steroid hormone receptor co-chaperone FKBPL are associated with male infertility: a case-control study. Reprod Biol Endocrinol 2010; 8: 22.
31. McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, et al. FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy. Cancer Res 2010; 70: 1090-100.
32. Pfosser A, Thalgott M, Buttner K, Brouet A, Feron O, Boekstegers P, et al. Liposomal Hsp90 cDNA induces neovascularization via nitric oxide in chronic ischemia. Cardiovasc Res 2005; 65: 728-36.
33. Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004; 10: 4813-21.
34. Valentine A, O'Rourke M, Yakkundi A, Worthington J, Hookham M, Bicknell R, et al. FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin Cancer Res 2011; 17: 1044-56.
35. Cao G, Savani RC, Fehrenbach M, Lyons C, Zhang L, Coukos G, et al. Involvement of endothelial CD44 during in vivo angiogenesis. Am J Pathol 2006; 169: 325-36.
36. Bourguignon LYW. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 2008; 18: 251-9.
37. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009; 27: 404-10.
38. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-85.
39. Esser C, Alberti S, Hohfeld J. Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim Biophys Acta 2004; 1695: 171-88.
40. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001; 3: 93-6.
41. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperonedependent stabilization and degradation of p53 mutants. Oncogene 2008; 27: 3371-83.
42. Fan MY, Park A, Nephew KP. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol 2005; 19: 2901-14.
43. Xu WP, Marcu M, Yuan XT, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2 Neu. Proc Natl Acad Sci USA 2002; 99: 12847-52.
44. Kamynina E, Kauppinen K, Duan FP, Muakkassa N, Manor D. Regulation of proto-oncogenic Dbl by chaperone-controlled, ubiquitinmediated degradation. Mol Cell Biol 2007; 27: 1809-22.
45. Xin H, Xu XL, Li LY, Ning HX, Rong Y, Shang Y, et al. CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation. J Biol Chem 2005; 280: 20842-50.
46. Bento CF, Fernandes R, Ramalho J, Marques C, Shang F, Taylor A, et al. The chaperone-dependent ubiquitin ligase CHIP targets HIF-1alpha for degradation in the presence of methylglyoxal. PloS one 2010; 5: e15062.
47. Shang Y, Zhao X, Xu X, Xin H, Li X, Zhai Y, et al. CHIP functions an E3 ubiquitin ligase of Runx1. Biochem Biophys Res Commun 2009; 386: 242-6.
48. Jang KW, Lee JE, Kim SY, Kang MW, Na MH, Lee CS, et al. The C-terminus of Hsp70-interacting protein promotes Met receptor degradation. J Thorac Oncol 2011; 6 : 679-87.
49. Kajiro M, Hirota R, Nakajima Y, Kawanowa K, So-Ma K, Ito I, et al. The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat Cell Biol 2009; 11: 312-9.
50. Xu T, Zhou Q, Zhou J, Huang Y, Yan Y, Li W, et al. Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis. Cancer Sci 2011; 102: 959-66.
51. Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and antiangiogenic therapy in malignant gliomas revisited. Acta Neuropathol 2012; 124: 763-75.
52. Wang SY, Wu XM, Zhang JB, Chen YS, Xu J, Xia XW, et al. CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut 2013; 62: 496-508.
53. Nurnberg W, Tobias D, Otto F, Henz BM, Schadendorf D. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 1999; 189: 546-51.
54. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6: 447-58.
55. Li X, Liu Q, Liu S, Zhang J, Zhang Y. New member of the guanosine triphosphatase activating protein family in the human epididymis. Acta Biochim Biophys Sin 2008; 40: 855-63.
56. Maeda M, Hasegawa H, Hyodo T, Ito S, Asano E, Yuang H, et al. ARHGAP18, a GTPase-activating protein for RhoA, controls cell shape, spreading, and motility. Mol Biol Cell 2011; 22: 3840-52.
57. Hahn CN, Su ZJ, Drogemuller CJ, Tsykin A, Waterman SR, Brautigan PJ, et al. Expression profiling reveals functionally important genes and coordinately regulated signaling pathway genes during in vitro angiogenesis. Physiol Genomics 2005; 22: 57-69.
58. Coleman PR, Hahn CN, Grimshaw M, Lu Y, Li X, Brautigan PJ, et al. Stress-induced premature senescence mediated by a novel gene, SENEX, results in an anti-inflammatory phenotype in endothelial cells. Blood 2010; 116: 4016-24.
59. van Buul JD, Geerts D, Huveneers S. Rho GAPs and GEFs: controling switches in endothelial cell adhesion. Cell Adh Migr 2014; 8: 108-24.
60. Chang GH, Lay AJ, Ting KK, Zhao Y, Coleman PR, Powter EE, et al. ARHGAP18: an endogenous inhibitor of angiogenesis, limiting tip formation and stabilizing junctions. Small GTPases 2014; 5: 1-15.
61. Blanco R, Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med 2013; 3: a006569.
62. Rabiet MJ, Plantier JL, Rival Y, Genoux Y, Lampugnani MG, Dejana E. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol 1996; 16: 488-96.
63. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009; 7: 511-22.
64. Stefansson OA, Jonasson JG, Olafsdottir K, Bjarnason H, Th Johannsson O, Bodvarsdottir SK, et al. Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression. Breast Cancer Res 2011; 13: R95.
65. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-50.
66. Uebelhoer M, Natynki M, Kangas J, Mendola A, Nguyen HL, Soblet J, et al. Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. Hum Mol Genet 2013; 22: 3438-48.
67. Paulsson M, Heinegård D. Radioimmunoassay of the 148-kilodalton cartilage protein. Distribution of the protein among bovine tissues. Biochem J 1982; 207: 207-13.
68. Christian S, Ahorn H, Novatchkova M, Garin-Chesa P, Park JE, Weber G, et al. Molecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endothelium. J Biol Chem 2001; 276: 48588-95.
69. Sanz-Moncasi MP, Garin-Chesa P, Stockert E, Jaffe EA, Old LJ, Rettig WJ. Identification of a high molecular weight endothelial cell surface glycoprotein, endoGlyx-1, in normal and tumor blood vessels. Lab Invest 1994; 71: 366-73.
70. Lorenzon E, Colladel R, Andreuzzi E, Marastoni S, Todaro F, Schiappacassi M, et al. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene 2012; 31: 3136-47.
71. Ribatti D, Nico B, Vacca A, Presta M. The gelatin spongechorioallantoic membrane assay. Nat Protoc 2006; 1: 85-91.
72. Kupprion C, Motamed K, Sage EH. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J Biol Chem 1998; 273: 29635-40.
73. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000; 96: 3772-8.
74. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387: 917-21.
75. Lebel E, Vallieres L, Rivest S. Selective involvement of interleukin-6 in the transcriptional activation of the suppressor of cytokine signaling-3 in the brain during systemic immune challenges. Endocrinology 2000; 141: 3749-63.
76. Jiang Y, Zhang Q, Soderland C, Steinle JJ. TNFalpha and SOCS3 regulate IRS-1 to increase retinal endothelial cell apoptosis. Cell Signal 2012; 24: 1086-92.
77. Dey BR, Furlanetto RW, Nissley P. Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem Biophys Res Commun 2000; 278: 38-43.
78. Stahl A, Joyal JS, Chen J, Sapieha P, Juan AM, Hatton CJ, et al. SOCS3 is an endogenous inhibitor of pathologic angiogenesis. Blood 2012; 120: 2925-9.
79. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101-11.
80. Stahl A, Connor KM, Sapieha P, Chen J, Dennison RJ, Krah NM, et al. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci 2010; 51: 2813-26.
81. Sapieha P, Stahl A, Chen J, Seaward MR, Willett KL, Krah NM, et al. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids. Sci Transl Med 2011; 3:69ra12.
82. Roberts AW, Robb L, Rakar S, Hartley L, Cluse L, Nicola NA, et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA 2001; 98: 9324-9.
83. Lofqvist C, Willett KL, Aspegren O, Smith AC, Aderman CM, Connor KM, et al. Quantification and localization of the IGF/insulin system expression in retinal blood vessels and neurons during oxygeninduced retinopathy in mice. Invest Ophthalmol Vis Sci 2009; 50: 1831-7.
84. Shaw LC, Pan H, Afzal A, Calzi SL, Spoerri PE, Sullivan SM, et al. Proliferating endothelial cell-specific expression of IGF-I receptor ribozyme inhibits retinal neovascularization. Gene Ther 2006; 13: 752-60.
85. Sasi SP, Yan X, Enderling H, Park D, Gilbert HY, Curry C, et al. Breaking the 'harmony' of TNF-alpha signaling for cancer treatment. Oncogene 2012; 31: 4117-27.
86. Kociok N, Radetzky S, Krohne TU, Gavranic C, Joussen AM. Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor-deficient mice. Invest Ophthalmol Vis Sci 2006; 47: 5057-65.
87. Stahl A, Joyal JS, Chen J, Sapieha P, Juan AM, Hatton CJ, et al. SOCS3 is an endogenous inhibitor of pathologic angiogenesis. Blood 2012; 120: 2925-9.
88. Ying MZ, Li DW, Yang LJ, Wang M, Wang N, Chen Y, et al. Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J Cancer Res Clin 2010; 136: 1617-26.
89. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-19.
90. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M, et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998; 188: 1763-8.
91. Nozell S, Wu Y, McNaughton K, Liu G, Willis A, Paik JC, et al. Characterization of p73 functional domains necessary for transactivation and growth suppression. Oncogene 2003; 22: 4333-47.
92. Wang JL, Liu X, Hande MP, Wong AC, Jin YJ, Yin YX. TAp73 is a downstream target of p53 in controlling the cellular defense against stress. J Biol Chem 2007; 282: 29152-62.
93. Chen DS, Ming LH, Zou FD, Peng Y, Van Houten B, Yu J, et al. TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity. Oncotarget 2014; 5: 8107-22.
94. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
95. Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat 2003; 21: 182-91.
96. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Gene Dev 2008; 22: 2677-91.
97. Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, et al. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol 2013; 15: 991-1000.
98. Salimath B, Marme D, Finkenzeller G. Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene 2000; 19: 3470-6.
99. Vikhanskaya F, Bani MR, Borsotti P, Ghilardi C, Ceruti R, Ghisleni G, et al. p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene 2001; 20: 7293-300.
100. Amelio I, Inoue S, Markert EK, Levine AJ, Knight RA, Mak TW, et al. TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1 alpha degradation. Proc Natl Acad Sci USA 2015; 112: 226-31.
101. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010; 16: 5928-35.
102. Han ZG, Zhang QH, Ye M, Kan LX, Gu BW, He KL, et al. Molecular cloning of six novel Kruppel-like zinc finger genes from hematopoietic cells and identification of a novel transregulatory domain KRNB. J Biol Chem 1999; 274: 35741-8.
103. Wang HY, Sun RL, Liu GX, Yao MH, Fei J, Shen HB. Characterization of the target DNA sequence for the DNA-binding domain of zinc finger protein 191. Acta Biochim Biophys Sin 2008; 40: 704-10.
104. Edelstein LC, Collins T. The SCAN domain family of zinc finger transcription factors. Gene 2005; 359: 1-17.
105. Khalfallah O, Faucon-Biguet N, Nardelli J, Meloni R, Mallet J. Expression of the transcription factor Zfp191 during embryonic development in the mouse. Gene Expr Patterns 2008; 8: 148-54.
106. Li JZ, Chen X, Yang H, Wang SL, Guo BY, Yu L, et al. The zinc finger transcription factor 191 is required for early embryonic development and cell proliferation. Exp Cell Res 2006; 312: 3990-8.
107. Howng SYB, Avila RL, Emery B, Traka M, Lin WS, Watkins T, et al. ZFP191 is required by oligodendrocytes for CNS myelination. Gene Dev 2010; 24: 301-11.
108. Lv L, Zhang J, Wang P, Meng Q, Liang W, Zhang L. Zinc finger protein 191 deficiency attenuates vascular smooth muscle cell proliferation, migration, and intimal hyperplasia after endovascular arterial injury. J Vasc Surg 2014; 59: 500-9.
109. Rousseau-Merk M F, Huebner K, Berger R, Thiesen H J . Chromosomal localization of two human zinc finger protein genes, ZNF24 (KOX17) and ZNF29 (KOX26), to 18q12 and 17p13-p12, respectively. Genomics 1991; 9: 154-61.
110. Kern SE, Fearon ER, Tersmette KW, Enterline JP, Leppert M, Nakamura Y, et al. Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA 1989; 261: 3099-103.
111. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
112. Papadimitrakopoulou VA, Oh Y, El-Naggar A, Izzo J, Clayman G, Mao L. Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. Clin Cancer Res 1998; 4: 539-44.
113. Richard F, Pacyna-Gengelbach M, Schluns K, Fleige B, Winzer KJ, Szymas J, et al. Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 2000; 89: 305-10.
114. Harper J, Yan L, Loureiro RM, Wu I, Fang J, D'Amore PA, et al. Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. Cancer Res 2007; 67: 8736-41.
115. Zhang H, Cui Y, Yu L. Expression of ZNF191 mRNA in ovarian malignant tumors. Acad J Sec Mil Med Univ 2003; 24: 1381-2. Chinese.
116. Liu G, Jiang S, Wang C, Jiang W, Liu Z, Liu C, Saiyin H, et al. Zinc finger transcription factor 191, directly binding to beta-catenin promoter, promotes cell proliferation of hepatocellular carcinoma; Hepatology 2012; 55: 1830-9.
117. Li J, Chen X, Liu Y, Ding L, Qiu L, Hu Z, et al. The transcriptional repression of platelet-derived growth factor receptor-beta by the zinc finger transcription factor ZNF24. Biochem Biophys Res Commun 2010; 397: 318-22.
118. Zhang J, Cao R, Zhang Y, Jia T, Cao Y, Wahlberg E. Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB J 2009; 23: 153-63.
119. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004; 15: 275-86.
120. Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, et al. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood 2013; 121: 707-15.
121. Jia D, Huang L, Bischoff J, Moses MA. The endogenous zinc finger transcription factor, ZNF24, modulates the angiogenic potential of human microvascular endothelial cells. FASEB J 2015; 29: 1371-82.
122. Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G proteincoupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci USA 2006; 103: 9023-8.
123. Yang L, Chen G, Mohanty S, Scott G, Fazal F, Rahman A, et al. GPR56 regulates VEGF production and angiogenesis during melanoma progression. Cancer Res 2011; 71: 5558-68.
124. Yang L, Xu L. GPR56 in cancer progression: current status and future perspective. Future Oncol 2012; 8: 431-40.
125. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997; 90: 4153-61.
126. Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP, et al. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J Exp Med 1998; 188: 1135-45.
127. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: proand antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-33.
128. Shi GZ, Yuan Y, Jiang GJ, Ge ZJ, Zhou J, Gong DJ, et al. PRAF3 induces apoptosis and inhibits migration and invasion in human esophageal squamous cell carcinoma. BMC Cancer 2012; 12: 97.
129. Chen H, Bai J, Ye J, Liu Z, Chen R, Mao W, et al. JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton. Cell Signal 2007; 19: 1315-27.
130. Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, et al. JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene 2010; 29: 1227-37.
131. Lu J, Tang Y, Farshidpour M, Cheng Y, Zhang G, Jafarnejad SM, et al. JWA inhibits melanoma angiogenesis by suppressing ILK signaling and is an independent prognostic biomarker for melanoma. Carcinogenesis 2013; 34: 2778-88.
132. Chen Y, Huang Y, Huang Y, Xia X, Zhang J, Zhou Y, et al. JWA suppresses tumor angiogenesis via Sp1-activated matrix metalloproteinase-2 and its prognostic significance in human gastric cancer. Carcinogenesis 2014; 35: 442-51.
133. Lu J, Tang Y, Cheng Y, Zhang G, Yip A, Martinka M, et al. ING4 regulates JWA in angiogenesis and their prognostic value in melanoma patients. Br J Cancer 2013; 109: 2842-52.
134. Noh YH, Matsuda K, Hong YK, Kunstfeld R, Riccardi L, Koch M, et al. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol 2003; 121: 1536-43.
135. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8: 349-57.
136. Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch TJ Jr. Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist 1999; 4: 501-8.
137. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003; 21: 223-31.
138. Rong B, Yang S, Li W, Zhang W, Ming Z. Systematic review and metaanalysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol 2012; 10: 170.
139. Ge W, Cao DD, Wang HM, Jie FF, Zheng YF, Chen Y. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pac J Cancer Prev 2011; 12: 2705-11.
140. Westphal JR. Technology evaluation: ABT-510, Abbott. Cur Opin Mol Ther 2004; 6: 451-7.